streptococcal vaccine - polysacchararide 14-valent
Trade name: Pneumovax
Vaccineapproved
Approved
Nov 21, 1977
Pneumococcal polysaccharide vaccine, sold under the brand name Pneumovax 23, is a pneumococcal vaccine that is used for the prevention of pneumococcal disease caused by the 23 serotypes of Streptococcus pneumoniae contained in the vaccine as capsular polysaccharides. It is given by intramuscular or subcutaneous injection. — Wikipedia
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1970s
- Nov 21, 1977
Earliest FDA Approval
Indications
Approved for
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Approval history
- approvedNov 21, 1977
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
Also known as
- streptococcal vaccine - polysacchararide 14-valent